Skip to main content
SpringerLink
Log in

Adverse Effects of Low-Dose Aspirin in the Gastrointestinal Tract

  • Chapter
  • First Online:
NSAIDs and Aspirin

  • 2160 Accesses

Abstract

Low-dose aspirin (LDA) is now broadly administered for the prevention of cardiovascular and cerebrovascular diseases. However, aspirin, even at a low dose, induces adverse effects on both the upper and lower gastrointestinal tracts, which precludes patient adherence to the continuous administration of aspirin. A preventive strategy for LDA-induced upper GI tract injury is being established, and the risk factors include histories of peptic ulcer diseases and concomitant intake of nonsteroidal anti-inflammatory drugs, antiplatelet agents, anticoagulants, and oral steroids. Patients with these risk factors should be coadministered gastroprotective drugs, such as proton pump inhibitors, to prevent upper GI adverse events. By contrast, a preventive strategy for LDA-induced lower GI tract injury remains to be established, although new endoscopic techniques, such as capsule endoscopy and double balloon endoscopy, yield images of small intestinal injury induced by LDA. Because lower GI bleeding has increased in LDA users, whereas upper bleeding has decreased, a preventive strategy for LDA-induced lower GI tract injury must be urgently established.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Yeomans ND, Lanas AI, Talley NJ, Thomson AB, Daneshjoo R, Eriksson B, et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther. 2005;22:795–801.

    Article  CAS  PubMed  Google Scholar 

  2. Serrano P, Lanas A, Arroyo MT, Ferreira IJ. Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. Aliment Pharmacol Ther. 2002;16:1945–53.

    Article  CAS  PubMed  Google Scholar 

  3. Lanas A, García-Rodríguez LA, Polo-Tomás M, Ponce M, Alonso-Abreu I, Perez-Aisa MA, Perez-Gisbert J, Bujanda L, Castro M, Muñoz M, Rodrigo L, Calvet X, Del-Pino D, Garcia S. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am J Gastroenterol. 2009;104:1633–41.

    Article  PubMed  Google Scholar 

  4. Casado Arroyo R, Polo-Tomas M, Roncalés MP, Scheiman J, Lanas A. Lower GI bleeding is more common than upper among patients on dual antiplatelet therapy: long-term follow-up of a cohort of patients commonly using PPI co-therapy. Heart. 2012;98:718–23.

    Article  PubMed  Google Scholar 

  5. Sostres C, Gargallo CJ. Gastrointestinal lesions and complications of low-dose aspirin in the gastrointestinal tract. Best Pract Res Clin Gastroenterol. 2012;26:141–51.

    Article  CAS  PubMed  Google Scholar 

  6. García Rodríguez LA, Hernández-Díaz S, de Abajo FJ. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol. 2001;52:563–71.

    Article  PubMed  Google Scholar 

  7. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ. 2000;321(7270):1183–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Iijima K, Ara N, Abe Y, Koike T, Iwai W, Iwabuchi T, Ichikawa T, Kamata Y, Ishihara K, Shimosegawa T. Association of gastric acid and mucus secretion level with low-dose aspirin-induced gastropathy. J Gastroenterol. 2012;47:150–8.

    Article  CAS  PubMed  Google Scholar 

  9. Iijima K, Iwabuchi T, Ara N, Koike T, Shinkai H, Kamata Y, Ichikawa T, Ishihara K, Shimosegawa T. Reactive increase in gastric mucus secretion is an adaptive defense mechanism against low-dose aspirin-induced gastropathy. Dig Dis Sci. 2013;58:2266–74.

    Article  CAS  PubMed  Google Scholar 

  10. Wallace JL. Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn’t the stomach digest itself? Physiol Rev. 2008;88:1547–65.

    Article  CAS  PubMed  Google Scholar 

  11. Laine L, Takeuchi K, Tarnawski A. Gastric mucosal defense and cytoprotection: bench to bedside. Gastroenterology. 2008;135:41–60.

    Article  CAS  PubMed  Google Scholar 

  12. Kitahora T, Guth PH. Effect of aspirin plus hydrochloric acid on the gastric mucosal microcirculation. Gastroenterology. 1987;93:810–7.

    Article  CAS  PubMed  Google Scholar 

  13. Rowe PH, Starlinger MJ, Kasdon E, Hollands MJ, Silen W. Parenteral aspirin and sodium salicylate are equally injurious to the rat gastric mucosa. Gastroenterology. 1987;93:863–71.

    Article  CAS  PubMed  Google Scholar 

  14. Sugano K. Prevention of Upper Gastrointestinal Ulcer and Complications in Low-Dose Aspirin Users. Curr Pharm Des. 2015;21:5082–8.

    Article  CAS  PubMed  Google Scholar 

  15. Wallace JL, Keenan CM, Granger DN. Gastric ulceration induced by nonsteroidal anti-inflammatory drugs is a neutrophil-dependent process. Am J Physiol. 1990;259(3 Pt 1):G462–7.

    CAS  PubMed  Google Scholar 

  16. Malfertheiner P, Chan FK, McColl KE. Peptic ulcer disease. Lancet. 2009;374(9699):1449–61. Review.

    Article  CAS  PubMed  Google Scholar 

  17. Cayla G, Collet JP, Silvain J, Thiefin G, Woimant F, Montalescot G. Prevalence and clinical impact of Upper Gastrointestinal Symptoms in subjects treated with low dose aspirin: the UGLA survey. Int J Cardiol. 2012;156(1):69–75.

    Article  PubMed  Google Scholar 

  18. Biondi-Zoccai GG, Lotrionte M, Agostoni P, Abbate A, Fusaro M, Burzotta F, Testa L, Sheiban I, Sangiorgi G. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J. 2006;27:2667–74.

    Article  PubMed  Google Scholar 

  19. Hsu PI, Tsai TJ. Epidemiology of Upper Gastrointestinal Damage Associated with Low-Dose Aspirin. Curr Pharm Des. 2015;21(35):5049–55.

    Article  CAS  PubMed  Google Scholar 

  20. Lanas A, Gargallo CJ. Management of low-dose aspirin and clopidogrel in clinical practice: a gastrointestinal perspective. J Gastroenterol. 2015;50:626–37.

    Article  CAS  PubMed  Google Scholar 

  21. Uemura N, Sugano K, Hiraishi H, Shimada K, Goto S, Uchiyama S, Okada Y, Origasa H, Ikeda Y, MAGIC Study Group. Risk factor profiles, drug usage, and prevalence of aspirin-associated gastroduodenal injuries among high-risk cardiovascular Japanese patients: the results from the MAGIC study. J Gastroenterol. 2014;49:814–24.

    Article  PubMed  Google Scholar 

  22. Iijima K, Shimosegawa T. Geographic differences in low-dose aspirin-associated gastroduodenal mucosal injury. World J Gastroenterol. 2015;21:7709–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Iijima K, Shimosegawa T. Risk Factors for Upper GI Damage in Low-Dose Aspirin Users and the Interaction Between H. pylori Infection and Low-Dose Aspirin Use. Curr Pharm Des. 2015;21:5056–65.

    Article  CAS  PubMed  Google Scholar 

  24. Laine L. Review article: gastrointestinal bleeding with low-dose aspirin—what’s the risk? Aliment Pharmacol Ther. 2006;24:897–908. Review.

    Article  CAS  PubMed  Google Scholar 

  25. Valkhoff VE, Sturkenboom MC, Kuipers EJ. Risk factors for gastrointestinal bleeding associated with low-dose aspirin. Best Pract Res Clin Gastroenterol. 2012;26:125–40.

    Article  CAS  PubMed  Google Scholar 

  26. Lanas A, Scheiman J. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr Med Res Opin. 2007;23:163–73. Review.

    Article  CAS  PubMed  Google Scholar 

  27. Leontiadis GI, Molloy-Bland M, Moayyedi P, Howden CW. Effect of comorbidity on mortality in patients with peptic ulcer bleeding: systematic review and meta-analysis. Am J Gastroenterol. 2013;108:331–45.

    Article  PubMed  Google Scholar 

  28. Marmo R, Koch M, Cipolletta L, Bianco MA, Grossi E, Rotondano G, PNED 2 Investigators. Predicting mortality in patients with in-hospital nonvariceal upper GI bleeding: a prospective, multicenter database study. Gastrointest Endosc. 2014;79:741–9.

    Article  PubMed  Google Scholar 

  29. García Rodríguez LA, Lin KJ, Hernández-Díaz S, Johansson S. Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. Circulation. 2011;123:1108–15.

    Article  PubMed  Google Scholar 

  30. Masclee GM, Valkhoff VE, Coloma PM, de Ridder M, Romio S, Schuemie MJ, Herings R, Gini R, Mazzaglia G, Picelli G, Scotti L, Pedersen L, Kuipers EJ, van der Lei J, Sturkenboom MC. Risk of upper gastrointestinal bleeding from different drug combinations. Gastroenterology. 2014;147:784–92.

    Article  CAS  PubMed  Google Scholar 

  31. Fletcher EH, Johnston DE, Fisher CR, Koerner RJ, Newton JL, Gray CS. Systematic review: Helicobacter pylori and the risk of upper gastrointestinal bleeding risk in patients taking aspirin. Aliment Pharmacol Ther. 2010;32:831–9.

    Article  CAS  PubMed  Google Scholar 

  32. Iijima K, Ara N, Abe Y, Koike T, Iwabuchi T, Shinkai H, Uno K, Endo H, Asano N, Shimosegawa T. Biphasic effects of H. pylori infection on low-dose aspirin-induced gastropathy depending on the gastric acid secretion level. J Gastroenterol. 2012;47:1290–7.

    Article  CAS  PubMed  Google Scholar 

  33. Iijima K, Ara N, Abe Y, Koike T, Iwai W, Uno K, Asano N, Imatani A, Ohara S, Shimosegawa T. Gastric acid secretion level modulates the association between Helicobacter pylori infection and low-dose aspirin-induced gastropathy. J Gastroenterol. 2011;46:612–9.

    Article  CAS  PubMed  Google Scholar 

  34. Iijima K, Koike T, Ara N, Nakagawa K, Kondo Y, Uno K, Hatta W, Asano N, Imatani A, Shimosegawa T. Identification of a high-risk group for low-dose aspirin-induced gastropathy by measuring serum pepsinogen in H. pylori-infected subjects. J Gastroenterol. 2015;50:305–12.

    Article  CAS  PubMed  Google Scholar 

  35. Hatta W, Iijima K, Koike T, Kondo Y, Ara N, Asanuma K, Uno K, Asano N, Imatani A, Shimosegawa T. Endoscopic findings for predicting gastric acid secretion status. Dig Endosc. 2015;27:582–9.

    Article  PubMed  Google Scholar 

  36. Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB, Furberg CD, Johnson DA, Kahi CJ, Laine L, Mahaffey KW, Quigley EM, Scheiman J, Sperling LS, Tomaselli GF, ACCF/ACG/AHA. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol. 2010;105:2533–49.

    Article  PubMed  Google Scholar 

  37. Chan FK, Goto S, Wu MS, Abola MT, Yeoh KG, Sutrisna B, Chua SS, Mahachai V, Turajane T, Wu B, Zeng QY, Sugano K. Burden of nonsteroidal anti-inflammatory and antiplatelet drug use in Asia: a multidisciplinary working party report. Clin Gastroenterol Hepatol. 2012;10:753–60.

    Article  PubMed  Google Scholar 

  38. Sugano K, Choi MG, Lin JT, Goto S, Okada Y, Kinoshita Y, Miwa H, Chiang CE, Chiba T, Hori M, Fukushima Y, Kim HS. Chang CY; on behalf of the LAVENDER Study Group. Multinational, double-blind, randomised, placebo-controlled, prospective study of esomeprazole in the prevention of recurrent peptic ulcer in low-dose acetylsalicylic acid users: the LAVENDER study. Gut. 2014;63:1061–8.

    Article  CAS  PubMed  Google Scholar 

  39. Scheiman JM, Devereaux PJ, Herlitz J, et al. Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON). Heart. 2011;97:797–802.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Yeomans N, Lanas A, Labenz J, et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol. 2008;103:2465–73.

    Article  CAS  PubMed  Google Scholar 

  41. Ekström P, Carling L, Wetterhus S, Wingren PE, Anker-Hansen O, Lundegårdh G, Thorhallsson E, Unge P. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study. Scand J Gastroenterol. 1996;31:753–8.

    Article  PubMed  Google Scholar 

  42. Yap PR, Goh KL. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Induced Dyspepsia. Curr Pharm Des. 2015;21:5073–81.

    Article  PubMed  Google Scholar 

  43. Taha AS, McCloskey C, Prasad R, Bezlyak V. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet. 2009;374(9684):119–25.

    Article  CAS  PubMed  Google Scholar 

  44. Lin KJ, Hernández-Díaz S, García Rodríguez LA. Acid suppressants reduce risk of gastrointestinal bleeding in patients on antithrombotic or anti-inflammatory therapy. Gastroenterology. 2011;141:71–9.

    Article  CAS  PubMed  Google Scholar 

  45. Ng FH, Wong SY, Lam KF, Chu WM, Chan P, Ling YH, Kng C, Yuen WC, Lau YK, Kwan A, Wong BC. Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology. 2010;138:82–8.

    Article  CAS  PubMed  Google Scholar 

  46. Donnelly MT, Goddard AF, Filipowicz B, Morant SV, Shield MJ, Hawkey CJ. Low-dose misoprostol for the prevention of low-dose aspirin-induced gastroduodenal injury. Aliment Pharmacol Ther. 2000;14:529–34.

    Article  CAS  PubMed  Google Scholar 

  47. Arakawa T, Kobayashi K, Yoshikawa T, Tarnawski A. Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig Dis Sci. 1998;43(9 Suppl):5S–13.

    CAS  PubMed  Google Scholar 

  48. Iijima K, Ichikawa T, Okada S, Ogawa M, Koike T, Ohara S, Shimosegawa T. Rebamipide, a cytoprotective drug, increases gastric mucus secretion in human: evaluations with endoscopic gastrin test. Dig Dis Sci. 2009;54:1500–7.

    Article  CAS  PubMed  Google Scholar 

  49. Tozawa K, Oshima T, Okugawa T, Ogawa T, Ohda Y, Tomita T, Hida N, Fukui H, Hori K, Watari J, Nakamura S, Miwa H. A randomized, double-blind, placebo-controlled study of rebamipide for gastric mucosal injury taking aspirin with or without clopidogrel. Dig Dis Sci. 2014;59:1885–90.

    Article  CAS  PubMed  Google Scholar 

  50. Yamamoto T, Isono A, Mishina Y, Ebato T, Shirai T, Nakayama S, Nagasawa K, Abe K, Hattori K, Ishii T, Kuyama Y. Gastroduodenal mucosal injury in patients taking low-dose aspirin and the role of gastric mucoprotective drugs: possible effect of rebamipide. J Clin Biochem Nutr. 2010;47:27–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Chan FK, Ching JY, Suen BY, Tse YK, Wu JC, Sung JJ. Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose aspirin users. Gastroenterology. 2013;144:528–35.

    Article  CAS  PubMed  Google Scholar 

  52. Malfertheiner P, Megraud F, O’Morain CA. et al; European Helicobacter Study Group. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut. 2012;61:646–64.

    Article  CAS  PubMed  Google Scholar 

  53. Pavlidis P, Bjarnason I. Aspirin Induced Adverse Effects on the Small and Large Intestine. Curr Pharm Des. 2015;21(35):5089–93.

    Article  CAS  PubMed  Google Scholar 

  54. Sostres C, Lanas A. Epidemiology of Low Dose Aspirin Damage in the Lower Gastrointestinal Tract. Curr Pharm Des. 2015;21:5094–100.

    Article  CAS  PubMed  Google Scholar 

  55. Higuchi K, Umegaki E, Watanabe T, Yoda Y, Morita E, Murano M, Tokioka S, Arakawa T. Present status and strategy of NSAIDs-induced small bowel injury. J Gastroenterol. 2009;44:879–88. Review.

    Article  PubMed  Google Scholar 

  56. Robert A, Asano T. Resistance of germ-free rats to indomethacin induced intestinal inflammation. Prostaglandins. 1977;14:333–41.

    Article  CAS  PubMed  Google Scholar 

  57. Smecuol E, Pinto Sanchez MI, Suarez A, Argonz JE, Sugai E, Vazquez H, Litwin N, Piazuelo E, Meddings JB, Bai JC, Lanas A. Low-dose aspirin affects the small bowel mucosa: results of a pilot study with a multidimensional assessment. Clin Gastroenterol Hepatol. 2009;7:524–9.

    Article  CAS  PubMed  Google Scholar 

  58. Hilsden RJ, Meddings JB, Sutherland LR. Intestinal permeability changes in response to acetylsalicylic acid in relatives of patients with Crohn’s disease. Gastroenterology. 1996;110:1395–403.

    Article  CAS  PubMed  Google Scholar 

  59. Leung WK, Bjarnason I, Wong VW, Sung JJ, Chan FK. Small bowel enteropathy associated with chronic low-dose aspirin therapy. Lancet. 2007;369(9561):614.

    Article  PubMed  Google Scholar 

  60. Endo H, Hosono K, Inamori M, Kato S, Nozaki Y, Yoneda K, Akiyama T, Fujita K, Takahashi H, Yoneda M, Abe Y, Kirikoshi H, Kobayashi N, Kubota K, Saito S, Matsuhashi N, Nakajima A. Incidence of small bowel injury induced by low-dose aspirin: a crossover study using capsule endoscopy in healthy volunteers. Digestion. 2009;79:44–51.

    Article  CAS  PubMed  Google Scholar 

  61. Moore RA, Derry S, McQuay HJ. Faecal blood loss with aspirin, nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 selective inhibitors: systematic review of randomized trials using autologous chromium-labelled erythrocytes. Arthritis Res Ther. 2008;10:R7. Review.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Fortun PJ, Hawkey CJ. Nonsteroidal antiinflammatory drugs and the small intestine. Curr Opin Gastroenterol. 2005;21:169–75. Review.

    Article  CAS  PubMed  Google Scholar 

  63. Longstreth GF. Epidemiology and outcome of patients hospitalized with acute lower gastrointestinal hemorrhage: a population-based study. Am J Gastroenterol. 1997;92:419–24.

    CAS  PubMed  Google Scholar 

  64. Strate LL, Liu YL, Huang ES, Giovannucci EL, Chan AT. Use of aspirin or nonsteroidal anti-inflammatory drugs increases risk for diverticulitis and diverticular bleeding. Gastroenterology. 2011;140:1427–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Yamada A, Sugimoto T, Kondo S, Ohta M, Watabe H, Maeda S, Togo G, Yamaji Y, Ogura K, Okamoto M, Yoshida H, Kawabe T, Kawase T, Omata M. Assessment of the risk factors for colonic diverticular hemorrhage. Dis Colon Rectum. 2008;51:116–20.

    Article  PubMed  Google Scholar 

  66. Nagata N, Niikura R, Aoki T, Shimbo T, Kishida Y, Sekine K, Tanaka S, Watanabe K, Sakurai T, Yokoi C, Akiyama J, Yanase M, Mizokami M, Uemura N. Colonic diverticular hemorrhage associated with the use of nonsteroidal anti-inflammatory drugs, low-dose aspirin, antiplatelet drugs, and dual therapy. J Gastroenterol Hepatol. 2014;29:1786–93.

    Article  CAS  PubMed  Google Scholar 

  67. Yuhara H, Corley DA, Nakahara F, Nakajima T, Koike J, Igarashi M, Suauki T, Mine T. Aspirin and non-aspirin NSAIDs increase risk of colonic diverticular bleeding: a systematic review and meta-analysis. J Gastroenterol. 2014;49:992–1000.

    Article  CAS  PubMed  Google Scholar 

  68. Hreinsson JP, Gumundsson S, Kalaitzakis E, Björnsson ES. Lower gastrointestinal bleeding: incidence, etiology, and outcomes in a population-based setting. Eur J Gastroenterol Hepatol. 2013;25:37–43.

    Article  PubMed  Google Scholar 

  69. Lanas A, Carrera-Lasfuentes P, Arguedas Y, García S, Bujanda L, Calvet X, Ponce J, Perez-Aísa Á, Castro M, Muñoz M, Sostres C, García-Rodríguez LA. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants. Clin Gastroenterol Hepatol. 2015;13:906–12.

    Article  PubMed  Google Scholar 

  70. Endo H, Sakai E, Taniguchi L, Kessoku T, Komiya Y, Ezuka A, Kawamura H, Taguri M, Higurashi T, Ohkubo H, Yamada E, Takahashi H, Inamori M, Maeda S, Sakaguchi T, Hata Y, Nagase H, Nakajima A. Risk factors for small-bowel mucosal breaks in chronic low-dose aspirin users: data from a prospective multicenter capsule endoscopy registry. Gastrointest Endosc. 2014;80:826–34.

    Article  PubMed  Google Scholar 

  71. Wallace JL, Syer S, Denou E, de Palma G, Vong L, McKnight W, Jury J, Bolla M, Bercik P, Collins SM, Verdu E, Ongini E. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology. 2011;141:1314–22.

    Article  CAS  PubMed  Google Scholar 

  72. Nagata N, Niikura R, Aoki T, Sakurai T, Moriyasu S, Shimbo T, Sekine K, Okubo H, Watanabe K, Yokoi C, Yanase M, Akiyama J, Uemura N. Effect of proton-pump inhibitors on the risk of lower gastrointestinal bleeding associated with NSAIDs, aspirin, clopidogrel, and warfarin. J Gastroenterol. 2015;50:1079–86.

    Article  CAS  PubMed  Google Scholar 

  73. Watanabe T, Sugimori S, Kameda N, Machida H, Okazaki H, Tanigawa T, Watanabe K, Tominaga K, Fujiwara Y, Oshitani N, Higuchi K, Arakawa T. Small bowel injury by low-dose enteric-coated aspirin and treatment with misoprostol: a pilot study. Clin Gastroenterol Hepatol. 2008;6:1279–82.

    Article  PubMed  Google Scholar 

  74. Endo H, Higurashi T, Hosono K, Sakai E, Sekino Y, Iida H, Sakamoto Y, Koide T, Takahashi H, Yoneda M, Tokoro C, Inamori M, Abe Y, Nakajima A. Efficacy of Lactobacillus casei treatment on small bowel injury in chronic low-dose aspirin users: a pilot randomized controlled study. J Gastroenterol. 2011;46:894–905.

    Article  PubMed  Google Scholar 

  75. Watanabe T, Nishio H, Tanigawa T, Yamagami H, Okazaki H, Watanabe K, Tominaga K, Fujiwara Y, Oshitani N, Asahara T, Nomoto K, Higuchi K, Takeuchi K, Arakawa T. Probiotic Lactobacillus casei strain Shirota prevents indomethacin-induced small intestinal injury: involvement of lactic acid. Am J Physiol Gastrointest Liver Physiol. 2009;297:G506–13.

    Article  CAS  PubMed  Google Scholar 

  76. Mizukami K, Murakami K, Abe T, Inoue K, Uchida M, Okimoto T, Kodama M, Fujioka T. Aspirin-induced small bowel injuries and the preventive effect of rebamipide. World J Gastroenterol. 2011;17:5117–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Watanabe T, Takeuchi T, Handa O, Sakata Y, Tanigawa T, Shiba M, Naito Y, Higuchi K, Fujimoto K, Yoshikawa T, Arakawa T. A multicenter, randomized, double-blind, placebo-controlled trial of high-dose rebamipide treatment for low-dose aspirin-induced moderate-to-severe small intestinal damage. PLoS One. 2015;10, e0122330.

    Article  PubMed  PubMed Central  Google Scholar 

  78. von Rahden BH, Germer CT. Pathogenesis of colonic diverticular disease. Langenbecks Arch Surg. 2012;397:1025–33.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, Akita, 010-8543, Japan

    Katsunori Iijima M.D.

Authors
  1. Katsunori Iijima M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katsunori Iijima M.D. .

Editor information

Editors and Affiliations

  1. IIS Aragón, CIBER Enfermedades Hepáicas y Digestivas (CIBERehd), Universidad de Zaragoza, Zaragoza, Spain

    Angel Lanas

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Iijima, K. (2016). Adverse Effects of Low-Dose Aspirin in the Gastrointestinal Tract. In: Lanas, A. (eds) NSAIDs and Aspirin. Springer, Cham. https://doi.org/10.1007/978-3-319-33889-7_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-33889-7_10

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-33887-3

  • Online ISBN: 978-3-319-33889-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation